Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05520138 · ClinicalTrials.gov registry record
Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
A clinical trial of Prostatic Neoplasms, Castration-Resistant, sponsored by Pfizer.
- Completed
- Registry status
- 5,506
- Enrollment target
- 1
- Study location
NCT05520138: Completed study of Prostatic Neoplasms, Castration-Resistant, sponsored by Pfizer.
NCT05520138 is a study of Prostatic Neoplasms, Castration-Resistant that has completed, run by Pfizer. The registered enrollment target is 5,506 participants, above the 190-participant average among 10 other Prostatic Neoplasms, Castration-Resistant trials with a reported enrollment target (2798% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05520138, a study of Prostatic Neoplasms, Castration-Resistant, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 5,506 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will be a retrospective data analysis to compare outcomes between patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) who initiated enzalutamide and those who initiated abiraterone using the 100% Fee-For-Service Medicare claims data. The study will address the following objectives: Primary objective: To compare overall survival (OS) in patients with chemotherapy-naïve mCRPC who initiated enzalutamide vs. abiraterone Secondary objectives: * To compare OS in patients with chemotherapy-naïve mCRPC who received only enzalutamide without any subsequent therapy vs. abiraterone without any subsequent therapy * To compare treatment duration and time to subsequent therapy in chemotherapy-naïve mCRPC patients initiating enzalutamide vs. abiraterone
Primary Outcome
OS (time to death) was defined as the time from the initiation of enzalutamide or abiraterone (i.e., index date) to the date of death. Participants who did not die were censored at their last available follow-up, which was defined as the earlier of disenrollment from Medicare or end of data availability. Kaplan-Meier method was used for analysis.
Conditions Studied
Interventions
- DRUG Enzalutamide
- DRUG Abiraterone acetate
Study Locations (1)
New York
- Pfizer Inc - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,506 participants |
| Start Date | 2022-08-29 |
| Est. Completion | 2023-06-30 |
What the finished NCT05520138 record still lists
NCT05520138 is an observational study that tracks outcomes without assigning an intervention. Its 5,506 participants enrollment target places it among the larger protocols in the corpus, above the 190-participant average among 10 other Prostatic Neoplasms, Castration-Resistant trials with a reported enrollment target (2798% higher).
The record links to 1 condition, with Prostatic Neoplasms, Castration-Resistant appearing as the primary indexed condition, and to 2 interventions - of which Enzalutamide is the first listed.
NCT05520138 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05520138 about?
NCT05520138 is a clinical study titled "Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)". This study will be a retrospective data analysis to compare outcomes between patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) who initiated enzalutamide and those who initiated abiraterone using the 100% Fee-For-Service Medicare claims data. The study will add...
What is the current status of trial NCT05520138?
This trial is currently completed. The enrollment target is 5,506 participants. The study started on 2022-08-29. Estimated completion is 2023-06-30.
What conditions does trial NCT05520138 study?
This clinical trial studies the following conditions: Prostatic Neoplasms, Castration-Resistant.
What interventions are being tested in trial NCT05520138?
The interventions under investigation include: Enzalutamide (DRUG), Abiraterone acetate (DRUG).
Who is sponsoring clinical trial NCT05520138?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05520138 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms, Castration-Resistant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05520138's enrollment target sits among peer trials
5,506 1st of 10 higher than 10 of 10 other Prostatic Neoplasms, Castration-Resistant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostatic Neoplasms, Castration-Resistant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
RECRUITING · Phase 1
-
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
-
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RECRUITING · Phase 1
-
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
RECRUITING · Phase 4
-
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 3
-
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05952557 · 5,500 participants · Phase 3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
- NCT06084234 · 5,500 participants · Phase 4
National Liver Cancer Screening Trial
- NCT07146568 · 5,515 participants · NA
Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hospital
- NCT04295486 · 5,478 participants · Phase 2
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI